Unlike KRAS mutations, which are very well characterized in CRC for their clinical consequences, as well as for their molecular and cellular effects on individual cancer hallmarks, there are fewer studies on NRAS mutants, most of which only report on their identification and their impact on lack of response to anti-EGFR therapy. The gene discussed is KRAS; the disease is colorectal carcinoma.